Trial Profile
A phase 2/3 adaptive design registration study in prostate cancer
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Noxopharm
- 29 Oct 2018 New trial record
- 22 Oct 2018 According to a Noxopharm media release, the company is planning to initiate this study in Q3 2019.